The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Open accessAbstract
Purpose: To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement. Patients and Methods: From May 2005 to June 2006 at our institute, we treated patients with previously pretreated CTCL or PTCLU using bortezomib as a single agent, at a dose of 1.3 mg/m 2 intravenously on days 1, 4, 8, and 11, every 21 days for a total of six cycles. Results: Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable. The overall response rate was 67%, with two (17%) complete remissions and six (50%) partial remissions. The remaining four patients had disease progression. Histologically, the responder patients were seven with CTCL and one with PTCLU with isolated skin involvement. All responses were durable, lasting from 7 to 14 or more months. Overall, the drug was well tolerated, with no grade 4 toxicity. The most common grade 3 toxicities were neutropenia (n = 2), thrombocytopenia (n = 2), and sensory neuropathy (n = 2). Conclusion: This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Committee on Hodgkin's Disease Staging Classification.
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., & Tubiana, M. (1971) · PubMed · Cited by 4,166
WHO-EORTC classification for cutaneous lymphomas
Willemze, R. (2005) · Blood · doi:10.1182/blood-2004-09-3502 · Cited by 3,803
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Willemze, R., Kerl, H., Sterry, W., Berti, E., Cerroni, L., Chimenti, M. S., Díaz-Pérez, J. L., Geerts, M., Goos, M., Knobler, R., et al. (1997) · PubMed · doi:10.1182/blood.v90.1.354 · Cited by 1,270
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.050 · Cited by 577
Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.108 · Cited by 526
Kaye, F. J., Bunn, P. A., Steinberg, S. M., Stocker, J. L., Ihde, D. C., Fischmann, A. B., Glatstein, E. J., Schechter, G. P., Phelps, R. M., Foss, F. M., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212603 · Cited by 487
Statistical Tables for the Design of Clinical Trials.
Wickham, C. A. C., Machin, D., & Campbell, M. J. (1988) · Journal of the Royal Statistical Society. Series A (Statistics in Society) · doi:10.2307/2982784 · Cited by 426
Sample size tables for exact single‐stage phase II designs
A'Hern, R. P. (2001) · Statistics in Medicine · doi:10.1002/sim.721 · Cited by 399
Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients
Zinzani, P. L., Baliva, G., Magagnoli, M., Bendandi, M., Modugno, G., Gherlinzoni, F., Orcioni, G. F., Ascani, S., Simoni, R., Pileri, S. A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2603 · Cited by 225
Self-citationMulticenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma
Wollina, U., Dummer, R., Brockmeyer, N. H., Konrad, H., Busch, J. ‐., Kaatz, M., Knopf, B., Koch, H., & Hauschild, A. (2003) · Cancer · doi:10.1002/cncr.11593 · Cited by 214
Sors, A., Jean-Louis, F., Pellet, C., Laroche, L., Dubertret, L., Courtois, G., Bachelez, H., & Michel, L. (2006) · Blood · doi:10.1182/blood-2005-06-2536 · Cited by 174
Proteasome inhibitor therapy in multiple myeloma
Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P., & Anderson, K. C. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0338 · Cited by 168
Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma: Phase II study of 32 patients
Marchi, E., Alinari, L., Tani, M., Stefoni, V., Pimpinelli, N., Berti, E., Pagano, L., Bernengo, M. G., Zaja, F., Rupoli, S., et al. (2005) · Cancer · doi:10.1002/cncr.21449 · Cited by 161
Self-citationIzban, K. F., Ergin, M., Qin, J. Z., Martinez, R. L., RJ, J. R. P., Saeed, S., & Alkan, S. (2000) · Human Pathology · doi:10.1053/hupa.2000.20370 · Cited by 123
Martínez–Delgado, B., Meléndez, B., Cuadros, M., Álvarez, J., Castrillo, J. M., de la Parte, A. R., Mollejo, M., Bellas, C., Díaz‐Uriarte, R., Lombardía, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0269 · Cited by 95
TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES
Baba, A. I., & Cătoi, C. (2007) · Cited by 93
Nasr, R., El-Sabban, M. E., Karam, J.-A., Dbaibo, G. S., Kfoury, Y. S., Arnulf, B., Lepelletier, Y., Bex, F., de Thé, H., Hermine, O., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208212 · Cited by 84
Proteasome Inhibitors as Therapy in Multiple Myeloma
Chauhan, D., Ajita, D., Singh, D., & Anderson, K. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_26 · Cited by 3
Cited by
Genomic landscape of cutaneous T cell lymphoma
Choi, J., Goh, G., Walradt, T., Hong, B. S., Bunick, C. G., Chen, K., Bjornson, R. D., Maman, Y., Wang, T., Tordoff, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3356 · Cited by 428
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.049 · Cited by 381
Foss, F. M., Zinzani, P. L., Vose, J. M., Gascoyne, R. D., Rosen, S. T., & Tobinai, K. (2011) · Blood · doi:10.1182/blood-2010-05-231548 · Cited by 353
Self-citationPrimary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.08.033 · Cited by 347
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0021 · Cited by 329
Metadata
- Authors
- Zinzani, P. L., Musuraca, G., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Alinari, L., Derenzini, E., de Vivo, A., Sabattini, E., Pileri, S., & Baccarani, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-09-20
- Volume
- 25
- Issue
- 27
- Pages
- 4293-4297
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2057290270
- Cited by
- 280
- References
- 21
- FWCI
- 18.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.